1. Home
  2. QH vs INTS Comparison

QH vs INTS Comparison

Compare QH & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QH

Quhuo Limited American Depository Shares

HOLD

Current Price

$5.80

Market Cap

14.8M

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$4.72

Market Cap

12.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QH
INTS
Founded
2012
2012
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.8M
12.9M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
QH
INTS
Price
$5.80
$4.72
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$38.00
AVG Volume (30 Days)
491.5K
64.3K
Earning Date
04-02-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.86
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.06
$0.19
52 Week High
$12.81
$8.06

Technical Indicators

Market Signals
Indicator
QH
INTS
Relative Strength Index (RSI) 50.31 66.87
Support Level $5.42 $4.50
Resistance Level $7.76 $8.06
Average True Range (ATR) 1.01 0.23
MACD -0.38 0.13
Stochastic Oscillator 18.55 83.34

Price Performance

Historical Comparison
QH
INTS

About QH Quhuo Limited American Depository Shares

Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services. It generates maximum of its revenue from the on-demand delivery solutions segment.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: